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Abstract
Objectives: Historically, only 10% of patients with hepatocellular carcinoma (HCC) are diagnosed with
early-stage, potentially curable disease. In this study, chronic hepatitis virus-infected patients were
prospectively screened to determine: (i) the proportion of patients diagnosed with potentially curable
HCC, and (ii) survival following curative therapy.
Methods: The study included 8900 chronic hepatitis virus-infected patients enrolled in a prospective
screening programme, of whom 1335 (15.0%) were infected with hepatitis B virus (HBV), 7120 (80.0%)
with hepatitis C virus (HCV), and 445 (5.0%) with both HBV and HCV. Screening was conducted every 6
months and included serum alpha-fetoprotein (AFP) measurement and ultrasonography. Curative treat-
ments included liver transplantation, resection, radiofrequency ablation and/or ethanol injection.
Results: Hepatocellular carcinoma was diagnosed in 765 (8.6%) patients. Of 1602 patients with cirrho-
sis, 758 (47.3%) developed HCC. Curative treatment was possible in 523 (68.4%) of the 765 HCC
patients. Two- and 5-year rates of overall survival in the curative treatment group were 65% and 28%,
respectively, compared with 10% and 0% in the advanced disease group (P < 0.001).
Conclusions: Prospective screening of patients at high risk for the development of HCC increases the
proportion of patients diagnosed with potentially curable disease. This may result in an increase in the
number of longterm survivors. Screening strategies should focus on patients with chronic HBV or HCV
infection who have progressed to cirrhosis because more than 40% of these patients will develop HCC.
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Introduction
Worldwide, hepatocellular carcinoma (HCC) remains the fifth
most common malignancy, following lung, breast, colorectal and
stomach carcinomas.1 Over 600 000 new cases were anticipated
in 2007.2 Despite the large number of new cases annually, there
remains a dearth of effective therapies for HCC and only
patients in the earliest stages of disease are eligible for curative
therapies such as transplantation, resection and tumour
ablation.3–8 Early-stage HCC accounts for only 10–30% of
patients at presentation.9 Typically, HCC is asymptomatic in the
early stages.
The vast majority of instances of HCC will arise in patients
chronically infected with hepatitis B virus (HBV) or hepatitis C
virus (HCV).2,10 Prior population-based studies have not indi-
cated any survival advantage to patients diagnosed during the
screening process, although this is controversial.11–14 Similarly, the
cost-effectiveness of screening populations in which HBV and
HCV infections are not endemic is not clear.15,16 Ostensibly, the
goal of screening for HCC is to detect early-stage disease and thus
to allow more patients to be treated with curative intent.
The present group instituted a prospective screening pro-
grammeof patients with chronicHBVorHCV infection according
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to the hypothesis that the screening of this populationwould result
in early detection of HCC and that more HCC patients would be
eligible for curative therapy.
This paper updates a previously published report from the
study institution.17
Materials and methods
Enrolment
Patients from the Campania region of Italy were enrolled into the
study. All patients were diagnosed serologically with chronic HBV
and/or HCV. Patients without chronic viral hepatitis were
excluded from the study. Enrolled patients were already undergo-
ing regular medical examinations for management of their
chronic viral hepatitis. A total of 8900 patients voluntarily
enrolled in this screening programme. The enrolment period
extended from 1993 to 2003 and the follow-up reported here was
documented to December 2008.
Each patient was required to have had a liver biopsy within a
year prior to enrolment or at the time of enrolment. This biopsy
was utilized to establish the underlying severity of hepatitis virus-
induced liver injury in each patient. The institutional clinical and
ethical review board at the G. Pascale National Cancer Institute,
Naples, Italy approved this study and all of its components.
Screening
The screening programme consisted of transabdominal ultra-
sonography and serum alpha-fetoprotein (AFP) measurement at
the time of enrolment. These two diagnostic tests were repeated at
6-month intervals for the duration of the study. Further diagnos-
tic investigation was instituted in patients in whom an AFP value
of >10 ng/ml was recorded or tumour was detected on ultra-
sonography. Patients in whom either or both of these findings
emerged during screening underwent computed tomography or
magnetic resonance imaging of the abdomen. The imaging
modality was selected at the discretion of the clinician. When
cross-sectional imaging resulted in findings suspicious for HCC,
the diagnosis was confirmed with percutaneous fine needle aspi-
ration biopsy. Equivocal fine needle aspiration results were con-
firmed with core needle biopsy.
Treatment
Once the diagnosis of HCC was established, the treatment modal-
ity was selected at the discretion of the clinician and patient based
on the stage of malignant disease and the severity of the underly-
ing chronic liver injury. Potentially curable lesions were treated
with surgical resection, hepatic transplantation or tumour abla-
tion. During the first 3 years of the enrolment period, ablation
therapy included percutaneous ethanol injection or percutaneous
radiofrequency ablation (RFA). After the initial 3 years, RFA alone
was utilized as tumour ablation therapy. In patients treated with
palliative intent, four potential modalities were considered: tran-
sarterial bland embolization; transarterial chemoembolization;
systemic chemotherapy, and best supportive care.
Statistical analysis
Chi-squared or Fisher’s exact tests were performed, as appropri-
ate, to assess the associations between treatment groups and sub-
groups, as well as number of tumours, local recurrence and
presence of lesions at follow-up. Patient characteristics were
tabulated and the Kruskal–Wallis test was used to determine
group differences based on age, tumour size and preoperative
AFP. The Kaplan–Meier method was used to estimate the distri-
bution of overall survival (OS) and the log-rank test was used to
compare survival between groups. Estimated median OS and
disease-free survival rates are reported with 95% confidence
intervals (CIs). A P-value of < 0.05 was considered to indicate
statistical significance. All analyses were performed using the Sta-
tistics Toolbox of matlab R2007a (MathWorks, Inc., Natick, MA,
USA).
Results
Patient demographics
The mean standard deviation (SD) age across the entire cohort
of patients (n = 8900) in the screening population was 58.8 7.7
years. The majority of patients were men (n = 6079, 68.3%).
Incidences of hepatitis virus infection and severity of parenchy-
mal injury in the study population are depicted in Table 1. At the
time of enrolment in the study, HCV was present in 80.0% of the
screening population and 1602 (18.0%) patients had cirrhosis.
The screening programme resulted in the detection of 765 cases
of HCC. The rate of false positive findings in the current screening
strategy was 7.4%.
The demographics of the screening programme population are
outlined in Table 2. Nearly all cases of HCC (n = 758, 99.1%)
occurred in patients with biopsy-proven cirrhosis (Child–Pugh
class A 29.2%, class B 52.1%, class C 18.7%) at the time of enrol-
ment in the screening programme. The other seven cases of HCC
developed in non-cirrhotic patients with severe chronic active
hepatitis.
Table 1 Proportions of 8900 patients enrolled in a prospective
screening trial for hepatocellular carcinoma with chronic hepatitis B
virus (HBV) or hepatitis C virus (HCV) infection, and severity of
viral-induced liver injury
Hepatitis type Patients, n (%)
HBV infection 1335 (15.0%)
HCV infection 7120 (80.0%)
HBV + HCV infection 445 (5.0%)
Hepatic parenchyma
Chronic active hepatitis: mild 5073 (57.0%)
Chronic active hepatitis: severe 2225 (25.0%)
Cirrhosis 1602 (18.0%)
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Treatment
Over two-thirds of patients with HCC (n = 523, 68.4%) were
treated with curative intent. Table 3 details the Child–Pugh clas-
sification of severity of cirrhosis in each treatment group. Hepatic
resection was initially utilized in 225 (43.0%) patients, over half of
whom were classified as having Child–Pugh class A disease.
Patients with Child–Pugh class B or C disease were medically
optimized and subsequently subjected to no more than single
segment resection or non-anatomic wedge resection at the discre-
tion of the treating surgeon. Radiofrequency ablation and/or per-
cutaneous ethanol injection were the primary therapies in 271
(51.8%) patients, 76.3% of whom were classified as having Child–
Pugh class B or C disease. Orthotopic liver transplantation was the
initial therapy in 27 (5.2%) patients, 88.9% of whom had Child–
Pugh class B or C disease. An analysis of the different groups of
patients (stratified according to Child–Pugh class) shows that
hepatic resection was the preferred treatment in Child–Pugh class
A patients (P < 0.001), RFA was most frequently adopted in
patients of Child–Pugh class B status (P < 0.001) and liver trans-
plantation was the preferred treatment in patients of Child–Pugh
class C status (P < 0.001).
Of those patients treated with palliative intent (n = 242), 196
(81.0%) were able to receive some type of therapy (transarterial
chemoembolization, transarterial bland embolization or systemic
chemotherapy). Nearly all of the 46 patients provided with best
supportive care (n = 43, 93.5%) were considered to have Child–
Pugh class B or C disease.
Overall survival of HCC patients
In the 765 patients with HCC, 5-year OS was 18% and 10-year OS
was 2%. Patients treated with curative intent demonstrated a sig-
nificantly improved OS outcome (5-year OS was 28% in patients
treated with curative intent and 0% in patients treated with pal-
liative intent; P = 0.00001). Ten-year OS in patients treated with
curative intent was 4%. In patients diagnosed with cirrhosis at
enrolment and subsequently diagnosed with HCC (n = 758,
99.1%), a significant survival advantage emerged for patients with
Child–Pugh class A cirrhosis compared with patients with class B
or C disease (5-year OS was 25% in class A patients, 15% in class
B patients and 12% in class C patients; P = 0.00001), regardless of
the type of potentially curative treatment.
The number of hepatic tumours present at diagnosis of HCC
also had an impact on OS. Patients with a solitary tumour had a
5-year OS rate of 33%, whereas patients with two or three hepatic
tumours at diagnosis achieved 5-year OS of 20% (P = 0.001). A
total of 122 (15.9%) cases of HCC were detected at the initial
screening visit. The majority (62.3%, n = 76) of patients in whom
HCC was detected at the initial screening had multiple tumours.
There were no 5-year survivors among patients in whom more
than three malignant hepatic tumours (41.8%, n = 51) or extra-
hepatic disease were present at diagnosis (P = 0.0001, compared
with patients with solitary tumours).
A comparison of patients stratified according to inciting viral
aetiology showed that HBV patients with HCC achieved better OS
than HCV patients with HCC (5-year OS was 21% in patients
with HBV infection and 15% in patients with HCV infection;
P = 0.006).
However, this survival advantage for HBV-infected patients was
not evident when HCC patients who underwent curative treat-
ment were evaluated (5-year OS in patients treated with curative
intent was 24% in HBV-infected patients and 25% in HCV-
infected patients; P = 0.83).
Discussion
The rationale for providing a screening programme is to offer to a
target population (at high risk for the development of a certain
disease) the possibility of early-stage diagnosis of asymptomatic
disease that is amenable to effective therapies. Clearly, the goal of
such a strategy is to increase the proportion of patients treated
with curative intent and to reduce disease-specific mortality. The
benefits of screening programmes must be calculated according to
the prevalence and socioeconomic impact of the disease in the
target population, and the economic impact of the screening strat-
egy. Screening for HCC has been shown to be feasible, but few
studies have demonstrated either community benefit or survival
benefit when screening is employed.11–15 Studies that evaluate
entire community populations regardless of risk level are likely to
comprise too large a patient pool to impact on HCC outcomes
economically, no matter how inexpensive the screening tools. This
would be especially true in Western countries, in which endemic
rates of HBV and HCV infection, albeit that they are rising, refer
to only a small fraction of the population.
In the case of HCC, cost-effectiveness studies have demon-
strated that an incidence of 1.5% per year would justify a sur-
veillance policy in patients with cirrhosis.18 Clear evidence is still
lacking in the case of patients without cirrhosis. As a result of
these concerns of economic and survival benefit, knowledge of the
appropriate population to enrol in a screening programme for
HCC remains elusive. In the present study, in order to maximize
efforts to improve HCC outcomes, the study population purpose-
fully included for screening only those patients with chronic active
Table 2 Characteristics of 765 patients diagnosed with hepatocellu-
lar carcinoma (HCC) among a screening population of 8900 patients
with chronic hepatitis B or C virus infection
Patients, n (%) 765 (8.6%)
Age, years, mean  SD (range) 60.0  9.8 (28–80)
HCC, initial screen, n (%) 122 (15.9%)
HCC, follow-up screen, n (%) 642 (83.9%)
Tumour size, cm, mean  SD (range) 3.6  1.8 (1.2–15.0)
Tumours, n, mean  SD (range) 2.0  1.5 (1–6)
AFP, ng/ml, mean  SD (range) 91  1840 (0.8–30 288)
SD, standard deviation; AFP, serum alpha fetoprotein.
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HBV or HCV infections because these were considered to repre-
sent those at the highest risk. The results derived from the entire
cohort of patients suggest that screening all patients with chronic,
active viral hepatitis still casts too wide a net to provide a cost-
effective programme because only 8% of high-risk patients
develop HCC. Recent research has demonstrated that HCC can
develop in patients without cirrhosis who are affected by chronic
active HCV infection and bridging fibrosis (Metavir score of F3).19
This finding and the use of transient elastography may offer the
possibility of stratifying different subsets of patients at risk for
HCC development and provide a rationale for the proposal of
targeted screening programmes in high-risk patients without cir-
rhosis with chronic HCV infection in order to increase the rate of
HCC diagnosis in this population. There is also evidence in the
literature to support the use of screening in patients affected by
chronic active HBV infection,mainly in Asian populations.20 Nev-
ertheless, the results of the current study do not seem to justify the
unselected screening of this class of patients in southern Italy.
Improvement in the rate of early diagnosis could be achieved by
selective screening of patients with chronic active HBV infection
who have a relatively higher risk for HCC, such as those with
alcohol problems, concomitant HCV infection or a family history
of HCC. Unfortunately, clear evidence in the field is still lacking.
In the present study, a subset analysis of patients who had
cirrhosis at the time of enrolment determined that screening was
beneficial in terms of detection. Surveillance of only these patients
with cirrhosis identified nearly all cases of HCC (99.1% in this
study) in the screening programme.As 68.4% of cirrhosis patients
with HCC were eligible for curative therapies at the time of detec-
tion, screening increased the pool of patients able to benefit from
intervention and may potentially result in improved longterm
disease-free and overall survival rates. Although the screening of
properly selected patients may reduce rates of cancer-related
death, its ultimate impact on longterm survival is difficult to
ascertain because of the significant rate of cirrhosis-related death
over time.
The false positive rate reported in the current study (7.4%) is
relatively low compared with those cited in other reports in the
literature.21 Nevertheless, the use of AFP values in the surveillance
setting has been questioned. Measurement of AFP proved to add
only 6–8% of detected cases compared with the use of ultrasonog-
raphy alone,22 which is not enough to counterbalance the high
false positive rate associated with the use of AFP levels in screen-
ing.22,23 In fact, only a small proportion of patients with early-stage
HCC (10–20%) present with an increase in serum AFP.24 In addi-
tion, fluctuating levels of serum AFP can reflect the exacerbation
of underlying liver disease or flares in viral infection, rather than
HCC development.25 For these reasons, the use of AFP as a sero-
logical test in the surveillance setting has not been recommended
in the European Association for the Study of the Liver and Euro-
pean Organization for Research and Treatment of Cancer (EASL–
EORTC) Clinical Practice Guidelines.26 Several alternative
markers such as des-gamma carboxyprothrombin or AFP-L3 have
been studied, but have failed to show any superiority over AFP.27,28
Currently, there is still a need for reliable serological markers to be
used in the surveillance setting as those available have failed to
offer substantial advantages over simple ultrasound surveillance
and probably carry an unjustified increase in the costs of screening
programmes.22,23 The current study was designed in the early
1990s, when the role of AFP was probably overestimated.
This update of this prospective study reveals that this screening
programme was able to detect HCC that was treatable with cura-
tive intent in 68.4% of the patients diagnosed and adds value to
the mid-term follow-up previously reported.17 However, HCC
remains difficult to treat with the armamentarium of therapeutics
currently available (5-year OS in HCC patients treated with cura-
tive intent in the present study was 28%). Clearly, the biology of
the disease is not impacted by early detection. The survival out-
comes reported in the present study are in line with those reported
in historical series29–33 and should be analysed in a manner that
takes into account the high percentage of patients presenting with
multiple tumours in the setting of advanced cirrhosis (Child–
Pugh class B or C disease). Underlying hepatic parenchymal
disease is likely to have contributed to the poor rate of OS in
patients treated with curative intent. Ostensibly, the main benefit
of screening may refer to the ability to detect more patients
with early-stage HCC who are eligible for resection, ablation or
transplantation.
The disappointing results in patients treated with curative
intent mitigate the benefits of the improved rate of early detection
in the screening programme. Because liver transplantation treats
both HCC and underlying chronic liver disease, it should be con-
sidered the optimal treatment for hepatitis virus-induced cirrho-
sis in patients diagnosed with early-stage HCC in a prospective
screening programme.34 It may be that OS would improve in a
population similar to that studied here if the use of liver trans-
plantation was more extensive, both as a first-line treatment and
as a secondary option after initial resective therapy.35,36 Unfortu-
Table 3 Child–Pugh class in 523 patients with hepatocellular carcinoma treated with curative intent
Treatment type Class A, n (%) Class B, n (%) Class C, n (%)
Hepatic resection 121 (53.8%) 101 (44.9%) 3 (1.3%)
RFA or PEI 65 (24.0%) 135 (49.8%) 71 (26.2%)
Transplantation 3 (11.1%) 9 (33.3%) 15 (55.6%)
RFA, radiofrequency ablation; PEI, percutaneous ethanol injection.
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nately, the paucity of donor organs continues to limit the potential
positive impact of this approach.
Previous research indicates that in a general population only
10–30% of patients presenting with HCC are eligible for curative
therapy.9,33 On the assumption that only 10% of early-stage
disease is detected in an unscreened population, the fact that 68%
of the HCC patients detected in the present study population were
found to have potentially curable disease implies that the screen-
ing programme enabled as many as 446 more patients to receive
potentially curative treatments than would have done in an
unscreened population of the same size. If the detection rate of
potentially curable lesions in an unscreened population is 30%,
the 68% detection rate afforded by the present programme reflects
the identification of an additional 294 patients.
The update of follow-up reported here supports proposals
for the instigation of screening strategies in patients with
chronic active hepatitis in the setting of underlying cirrhosis.
Screening broader populations in Western nations is unlikely to
increase the detection rate of potentially curable HCC and may be
cost-prohibitive.
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